Cell Robotics begins clinicals of laser skin perforator for blood sampling.
This article was originally published in The Gray Sheet
CELL ROBOTICS BEGINS CLINICALS ON LASER SKIN PERFORATOR following FDA approval of an investigational device exemption for the study July 25. The single-site trial at University of New Mexico Medical School in Albuquerque will compare use of the laser to conventional stainless steel lancets for collecting capillary blood samples, and focus on any changes in blood chemistry from device use. Cell Robotics, Inc. expects to complete the study in four to six weeks.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.